# Immunovant, Inc. (IMVT) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Immunovant, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2026 MD&A](/company/IMVT/mda/fy2026/): filed 2026-05-20; accession 0001764013-26-000064 (https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm); latest 10-K
- [FY 2025 MD&A](/company/IMVT/mda/fy2025/): filed 2025-05-29; accession 0001764013-25-000092 (https://www.sec.gov/Archives/edgar/data/1764013/000176401325000092/imvt-20250331.htm)
- [FY 2024 MD&A](/company/IMVT/mda/fy2024/): filed 2024-05-29; accession 0001764013-24-000109 (https://www.sec.gov/Archives/edgar/data/1764013/000176401324000109/imvt-20240331.htm)
- [FY 2023 MD&A](/company/IMVT/mda/fy2023/): filed 2023-05-22; accession 0001764013-23-000065 (https://www.sec.gov/Archives/edgar/data/1764013/000176401323000065/imvt-20230331.htm)
- [FY 2022 MD&A](/company/IMVT/mda/fy2022/): filed 2022-06-08; accession 0001764013-22-000059 (https://www.sec.gov/Archives/edgar/data/1764013/000176401322000059/imvt-20220331.htm)

Back to /company/IMVT/